ClinicalTrials.gg
Not yet recruitingNCT07070167ULISSESUpdated Jul 17, 2025

Bedside Ultrasound to Monitor Lung Function and Blood Flow in Newborns Treated With Surfactant

An observational study in Lung Ultrasound and Respiratory Distress Syndrome, Newborn, sponsored by Chiesi Poland Sp. z o.o.. Not yet recruiting at 2 sites in Poland. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Chiesi Poland Sp. z o.o. (part of Chiesi Farmaceutici S.p.A.) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Sex
All
01

Study summary

The ULISSES study looks at how doctors use bedside ultrasound to help treat premature babies with breathing problems caused by Respiratory Distress Syndrome (RDS). It focuses on whether doctors decide to give a medicine called surfactant based on oxygen levels alone or if they also use lung ultrasound images to guide their decision.

Around 200 babies will take part in the study in hospitals across Poland. Doctors will do ultrasound scans of the babies' lungs before and after surfactant is given. In some hospitals, heart and lung blood flow will also be checked to look for signs of high blood pressure in the lungs.

The study will see if both lungs improve equally after treatment or if one side stays worse, and whether this affects how much breathing support the baby needs. The results may help doctors improve how and when they give surfactant, leading to better care for newborns with RDS.

Read the detailed description

The ULISSES study (Point-of-Care Ultrasonography for Assessing Lung Aeration and Pulmonary Vascular Resistance Dynamics After Surfactant Administration in Neonates With Respiratory Distress Syndrome) is a prospective, multicenter, non-interventional (observational) study involving approximately 200 preterm neonates across 10-12 tertiary-level neonatal intensive care units (NICUs) in Poland.

The study is designed to evaluate real-world practices related to the use of point-of-care lung ultrasound (LUS) in the decision-making process for surfactant therapy in neonates with Respiratory Distress Syndrome (RDS). The investigation is aligned with evolving European neonatal care guidelines that recommend incorporating LUS findings alongside traditional oxygen thresholds (FiO₂) when determining surfactant need.

All enrolled neonates will undergo a baseline lung ultrasound within the first 6 hours of life, prior to surfactant administration. LUS scoring will follow a validated 5-point scale (0-4) per lung quadrant, resulting in a total score between 0-16. A second LUS examination will be performed between 24 and 30 hours after surfactant administration to assess treatment response and identify any asymmetry in lung aeration, defined as a side-to-side LUS score difference ≥2 points.

In a subset of centers that routinely conduct neonatal hemodynamic assessments, echocardiographic evaluation of the main pulmonary artery (MPA) and ascending aorta (AA) diameters will be carried out. The MPA-to-AA ratio will serve as a surrogate marker of pulmonary vascular resistance and potential pulmonary hypertension. A ratio >1.3 will be considered indicative of clinically significant pulmonary arterial hypertension, consistent with published literature.

The surfactant treatment (product: Curosurf) will be administered per standard clinical practice, including both LISA (Less Invasive Surfactant Administration) and INSURE (INtubation, SURfactant administration, Extubation) methods. The mode of surfactant delivery and timing of administration will be recorded, as will any need for redosing.

Comprehensive clinical data-including gestational age, birth history, comorbidities, oxygenation parameters (SpO₂/FiO₂), and level and duration of respiratory support-will be collected through the neonatal hospital stay. Respiratory support will be categorized into escalating classes from spontaneous breathing to mechanical ventilation, to allow stratified analysis of post-surfactant respiratory outcomes.

The study will also explore associations between post-treatment lung ultrasound asymmetry, mode of surfactant delivery, and the presence of pulmonary comorbidities using multivariable logistic regression modeling.

All data will be collected in accordance with good clinical practice and applicable data protection regulations. As a non-interventional study, ULISSES is intended to provide evidence on the integration of bedside imaging into neonatal care, without altering routine clinical management.

The planned study duration is from end-July 2025 to December 2026.

02

Conditions studied

  • Lung Ultrasound
  • Respiratory Distress Syndrome, Newborn

Keywords

  • surfactant
03

In context

Respiratory Distress Syndrome, Newborn

123 studies on the registry are indexed under Respiratory Distress Syndrome, Newborn; 24 are open to participants now.

This study's planned enrollment of 200 is above the median of 150 across 25 observational studies indexed under Respiratory Distress Syndrome, Newborn.

Browse Respiratory Distress Syndrome, Newborn studies →

Lead sponsor

Chiesi Poland Sp. z o.o. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes preterm neonates born before 37 weeks of gestation with diagnosed or suspected Respiratory Distress Syndrome (RDS) who are considered for surfactant (SF) therapy based on the attending physician's judgment. Only infants managed initially without delivery room intubation are eligible, ensuring a baseline lung ultrasound (LUS) can be performed before SF administration.

Participants will be recruited from tertiary neonatal intensive care units in Poland, all experienced in neonatal ultrasound.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm neonates (gestational age \<37 weeks) with established Respiratory Distress Syndrome (RDS) or at risk for RDS
  • Decision of the use of surfactant by the attending physician

Exclusion criteria

Exclusion Criteria:

  • Presence of major congenital abnormalities of the respiratory system
  • Infants requiring primary intubation and mechanical ventilation in the delivery room
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

  • DrugIntratracheal administration of surfactant

    Intratracheal administration of pulmonary surfactant with any of the approved methods: (a) via endotracheal tube in a mechanically-ventilated infant, (b) with the INSURE method (intubation-surfactant-extubation), or (c) with LISA method (through a thin catheter inserted intratracheally in a spontaneously breathing infant, supported with CPAP)

06

What researchers measure

Primary outcomes

  1. Adoption of lung ultrasound in treatment decisions

    The rate of surfactant treatment decisions based on lung ultrasound score (LUS)\* versus those based on oxygen requirement\*\*. \*Definition of LUS-guided treatment: LUS score ≥6 points and FiO2 ≤0.30 before surfactant administration; \*\*Definition of FiO2-guided treatment:: FiO2 \>0.30, regardless of LUS score value before surfactant administration.

    Time frame: 1st day of life

Secondary outcomes

  1. Lung aeration asymmetry

    Percentage of infants presenting with the side-to-side lung ultrasound score difference ≥2 points at 24 hours after surfactant (SF) administration

    Time frame: From the time of SF administration to 24 hours (±6 hours) after the dose

Other outcomes

  1. Vascular resistance in the pulmonary circulation.

    Changes in the Main Pulmonary Artery to Ascending Aorta ratio (MPA-to-AA) at 24 hours post-surfactant (SF) compared to pre-SF value

    Time frame: From the time of SF administration to 24 hours (±6 hours) after the dose

07

Study locations

2 sites
  • Department of Neonatology, Czerwiakowski Hospital at Siemiradzki st., Cracow, Poland
    Krakow, 31137, Poland
  • Department of Neonatology and Neonatal Intensive Care, Medical University of Warsaw
    Warsaw, Poland
08

References and documents

Individual participant data

Plan to share: No — In accordance with the data protection policies of the Principal Investigator's institution, individual participant data (IPD) cannot be shared with external researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Dec 2026, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2025
First posted
Jul 17, 2025
StartEst.
Aug 30, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07070167
Collaborators
Polish Ultrasound Society, Neonatal Section
Responsible party
Sponsor
First posted
Jul 17, 2025
Start date
Aug 30, 2025 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jul 17, 2025

Study contacts

Piotr Kruczek, MD, PhD
Contact
kruczekpiotr@poczta.onet.pl
+48 12 634 2601

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion